These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 9830460)

  • 1. Pharmacological management of acute radiation morbidity.
    Zimmermann JS; Kimmig B
    Strahlenther Onkol; 1998 Nov; 174 Suppl 3():62-5. PubMed ID: 9830460
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Radioprotection: the non-steroidal anti-inflammatory drugs (NSAIDs) and prostaglandins.
    Lee TK; Stupans I
    J Pharm Pharmacol; 2002 Nov; 54(11):1435-45. PubMed ID: 12495545
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Radiation proctitis. Clinical and pathological manifestations, therapy and prophylaxis of acute and late injurious effects of radiation on the rectal mucosa.
    Zimmermann FB; Feldmann HJ
    Strahlenther Onkol; 1998 Nov; 174 Suppl 3():85-9. PubMed ID: 9830466
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapy and prophylaxis of acute and late radiation-induced sequelae of the esophagus.
    Zimmermann FB; Geinitz H; Feldmann HJ
    Strahlenther Onkol; 1998 Nov; 174 Suppl 3():78-81. PubMed ID: 9830464
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined treatment with cytoprotective agents and radiotherapy.
    Winczura P; Jassem J
    Cancer Treat Rev; 2010 May; 36(3):268-75. PubMed ID: 20044209
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antioxidants and other nutrients do not interfere with chemotherapy or radiation therapy and can increase kill and increase survival, part 1.
    Simone CB; Simone NL; Simone V; Simone CB
    Altern Ther Health Med; 2007; 13(1):22-8. PubMed ID: 17283738
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antioxidants and other nutrients do not interfere with chemotherapy or radiation therapy and can increase kill and increase survival, Part 2.
    Simone CB; Simone NL; Simone V; Simone CB
    Altern Ther Health Med; 2007; 13(2):40-7. PubMed ID: 17405678
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improving the morbidity of anorectal injury from pelvic radiotherapy.
    Abbasakoor F; Vaizey CJ; Boulos PB
    Colorectal Dis; 2006 Jan; 8(1):2-10. PubMed ID: 16519631
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trends in the development of radioprotective agents.
    Hosseinimehr SJ
    Drug Discov Today; 2007 Oct; 12(19-20):794-805. PubMed ID: 17933679
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical status of the new cytoprotective agent, amifostine.
    Kalaycioglu M; Bukowski R
    Oncology (Williston Park); 1994 Jul; 8(7):15-6, 19-20, 23. PubMed ID: 7522504
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current management for late normal tissue injury: radiation-induced fibrosis and necrosis.
    Delanian S; Lefaix JL
    Semin Radiat Oncol; 2007 Apr; 17(2):99-107. PubMed ID: 17395040
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic effect of oral recombinant human granulocyte macrophage-colony stimulating factor in radiotherapy-induced esophagitis.
    Koc M; Onuk MD; Koruk M; Memik F
    Hepatogastroenterology; 2003; 50(53):1297-300. PubMed ID: 14571722
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The impact of acute radiation morbidity on therapeutic outcome.
    Zimmermann JS; Feldmann HJ; Dörr W
    Strahlenther Onkol; 1998 Nov; 174 Suppl 3():1-3. PubMed ID: 9830446
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Radiation-induced xerostomia.
    Chambers MS; Rosenthal DI; Weber RS
    Head Neck; 2007 Jan; 29(1):58-63. PubMed ID: 16906511
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of postoperative radiation injury of the urinary bladder by hyperbaric oxygen (HBO).
    Peusch-Dreyer D; Dreyer KH; Müller CD; Carl U
    Strahlenther Onkol; 1998 Nov; 174 Suppl 3():99-100. PubMed ID: 9830470
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The treatment of late radiation effects with hyperbaric oxygenation (HBO).
    Plafki C; Carl UM; Glag M; Hartmann KA
    Strahlenther Onkol; 1998 Nov; 174 Suppl 3():66-8. PubMed ID: 9830461
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The impact of concurrent granulocyte macrophage-colony stimulating factor on radiation-induced mucositis in head and neck cancer patients: a double-blind placebo-controlled prospective phase III study by Radiation Therapy Oncology Group 9901.
    Ryu JK; Swann S; LeVeque F; Scarantino CW; Johnson D; Chen A; Fortin A; Pollock J; Kim H; Ang KK
    Int J Radiat Oncol Biol Phys; 2007 Mar; 67(3):643-50. PubMed ID: 17293228
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oral administration of recombinant human granulocyte macrophage colony-stimulating factor in the management of radiotherapy-induced esophagitis.
    Koukourakis MI; Flordellis CS; Giatromanolaki A; Koukouraki S; Kapsoritakis A; Potamianos S; Retalis G; Sivridis E; Salsaa B; Harris AL; Maragoudakis MI
    Clin Cancer Res; 1999 Dec; 5(12):3970-6. PubMed ID: 10632327
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacologic approaches to radiation protection.
    Brizel DM
    J Clin Oncol; 2007 Sep; 25(26):4084-9. PubMed ID: 17827457
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II multicenter randomized study of amifostine for prevention of acute radiation rectal toxicity: topical intrarectal versus subcutaneous application.
    Kouloulias VE; Kouvaris JR; Pissakas G; Mallas E; Antypas C; Kokakis JD; Matsopoulos G; Michopoulos S; Mystakidou K; Vlahos LJ
    Int J Radiat Oncol Biol Phys; 2005 Jun; 62(2):486-93. PubMed ID: 15890591
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.